.jpg?w=8688&max-h=5792&fit=crop&auto=format)
semaglutide new Dosage Forms Approved by FDA A new Medicare option for
Description
Liraglutide's main advantage is its completed cardiovascular outcomes trial (LEADER) demonstrating 13% MACE reduction, while tirzepatide's CVOT is still pending
This side effect wasnt reported in studies
Its a great option if you want to avoid waiting rooms or need medical help outside regular office hours
Providers market these combinations as offering additional benefits beyond weight management, though the evidence base for sublingual delivery of these combinations is similarly limited
